<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692598</url>
  </required_header>
  <id_info>
    <org_study_id>MID-002</org_study_id>
    <nct_id>NCT03692598</nct_id>
  </id_info>
  <brief_title>Study of Transcatheter Tricuspid Annular Repair</brief_title>
  <acronym>STTAR</acronym>
  <official_title>Study of Transcatheter Tricuspid Annular Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micro Interventional Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micro Interventional Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and performance of the MIA Minimally
      Invasive Annuloplasty Device in patients with chronic functional tricuspid regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the safety and performance of the MIA Minimally
      Invasive Annuloplasty Device in patients with chronic functional tricuspid regurgitation. The
      study is a prospective, multi-center safety and performance study. Enrolled subjects will be
      assessed for clinical follow-up at 1 month, 6 months, and 1 year post implant procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>The percentage of participants with Major Adverse Events within 30 days of the procedure: death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed MIA implantation, or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in tricuspid regurgitation at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>The reduction in the degree of tricuspid regurgitation compared to baseline measured post-procedure, at post-operative hospital discharge and at 1 month post-operative. Ability to reduce tricuspid regurgitation by at least 1 degree by means of quantitative echocardiographic parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADE)</measure>
    <time_frame>3 months</time_frame>
    <description>The percentage of participants with Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADE) within 6 months of the procedure will be compared to the literature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in tricuspid regurgitation</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment in the degree of Tricuspid Regurgitation at 3 months compared to baseline Ability to maintain improvement in tricuspid regurgitation with respect to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measurement</measure>
    <time_frame>3 months</time_frame>
    <description>Change in quality of life questionnaire (Minnesota Living with Heart Failure Questionnaire) compared to baseline at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>MIA Surgical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MIA Percutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIA, Minimally Invasive Annuloplasty Device - Surgical</intervention_name>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach</description>
    <arm_group_label>MIA Surgical</arm_group_label>
    <other_name>MIA-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIA, Minimally Invasive Annuloplasty Device - Percutaneous</intervention_name>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach</description>
    <arm_group_label>MIA Percutaneous</arm_group_label>
    <other_name>MIA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic functional tricuspid regurgitation (FTR) with a minimum of moderate tricuspid
             regurgitation (2-4)

          2. Age≥18 and ≤85 years old

          3. New York Heart Association (NYHA) Class II, III or ambulatory IV

          4. Left ventricular ejection fraction (LVEF) ≥30%

          5. Undergoing cardiac surgical procedure with the planned use of cardiopulmonary bypass
             (surgical arm only)

          6. Functional tricuspid valve regurgitation pathology with a structurally normal valve;
             and tricuspid valve annular diameter ≥ 40 mm (or 21 mm/m2) and ≤55 mm (or 29 mm/m2) or
             2-4 + FTR

          7. Patient provides written Informed Consent before any study-specific tests or
             procedures are performed

          8. Patient is willing and able to comply with all specified study evaluations

        Exclusion Criteria:

          1. Pregnant or lactating female

          2. Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg)

          3. Previous tricuspid valve repair or replacement

          4. Myocardial Infarction or known unstable angina within the 30-days prior to the index
             procedure

          5. Any PCI within 30 days prior to the index procedure or planned 3 months post the index
             procedure

          6. Life expectancy of less than 12-months

          7. Severe right heart dysfunction

          8. Pulmonary hypertension with PA mean 2/3 rd MAP

          9. Active systemic infection

         10. Pericardial infection

         11. Any clinical evidence that the investigator feels would place the patient at increased
             risk with the deployment of the device

         12. Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g.
             severe chronic obstructive pulmonary disease, hepatic failure, cardiac disease,
             autoimmune disorders or conditions of severe immunosuppression)

         13. Untreated coronary artery disease (CAD) requiring revascularisation unless CABG
             procedure is concomitant with MIA tricuspid annular repair (surgical arm only)

         14. Haemodynamic instability: systolic blood pressure &lt;90mmHg without reduction of
             afterload, shock, need for inotropic medication or IABP

         15. Active peptic ulcer or gastrointestinal (GI) bleeding in the past 3 months

         16. Cerebrovascular event within the past 6 months

         17. History of mitral/tricuspid endocarditis within the last 12 months

         18. Organic tricuspid disease

         19. Contraindication or known allergy to device's components, aspirin, anti-coagulation
             therapy or contrast media that cannot be adequately premeditated

         20. Known alcohol or drug abuser

         21. Currently participating in the study of an investigational drug or device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kestutis Rucinskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University Hospital, Santariskiu Klinikos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Willard Hennemann, PhD</last_name>
    <phone>215 600-1273</phone>
    <email>bhennemann@microinterventional.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy L West</last_name>
    <phone>6127566791</phone>
    <email>jwest@microinterventional.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steen H Poulsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bela Merkely</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre of Cardiology, Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimantas Benetis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kestutis Rucinskas, MD</last_name>
      <email>Kestutis.Rucinskas@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Vilius Janusauskus, MD</last_name>
      <email>Vilius.Janusauskas@santa.lt</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Cardinal Stefan Wyszyński Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Demkow</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

